IL142248A0 - Methods for treating sepsis - Google Patents

Methods for treating sepsis

Info

Publication number
IL142248A0
IL142248A0 IL14224899A IL14224899A IL142248A0 IL 142248 A0 IL142248 A0 IL 142248A0 IL 14224899 A IL14224899 A IL 14224899A IL 14224899 A IL14224899 A IL 14224899A IL 142248 A0 IL142248 A0 IL 142248A0
Authority
IL
Israel
Prior art keywords
methods
treating sepsis
sepsis
treating
Prior art date
Application number
IL14224899A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL142248A0 publication Critical patent/IL142248A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14224899A 1998-10-22 1999-10-15 Methods for treating sepsis IL142248A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10523998P 1998-10-22 1998-10-22
PCT/US1999/024409 WO2000023101A1 (en) 1998-10-22 1999-10-15 Methods for treating sepsis

Publications (1)

Publication Number Publication Date
IL142248A0 true IL142248A0 (en) 2002-03-10

Family

ID=22304754

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14224899A IL142248A0 (en) 1998-10-22 1999-10-15 Methods for treating sepsis

Country Status (9)

Country Link
US (2) US6344197B2 (xx)
EP (1) EP1124573A1 (xx)
JP (1) JP2002527490A (xx)
CN (1) CN1324244A (xx)
AU (1) AU768075B2 (xx)
BR (1) BR9914735A (xx)
CA (1) CA2347250A1 (xx)
IL (1) IL142248A0 (xx)
WO (1) WO2000023101A1 (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4746741B2 (ja) * 2000-12-14 2011-08-10 キヤノン株式会社 放射線撮像装置及びシステム
US7605130B2 (en) * 2002-03-26 2009-10-20 Medical College Of Ohio Albumin-based colloid composition and method of use in treating hypovolemia and multiorgan dysfunction
US7037895B2 (en) * 2001-03-27 2006-05-02 Medical College Of Ohio Albumin-based colloid composition and method of use in treating hypovolemia and multiorgan dysfunction
WO2002085117A1 (en) * 2001-04-24 2002-10-31 Eisai Co., Ltd. Methods and compositions for preventing and treating septic shock and endotoxemia
EP1417055A4 (en) * 2001-07-19 2007-09-26 Dmi Biosciences Inc USE OF COPPER CHELATORS TO PREVENT THE INACTIVATION OF PROTEIN C
US6838432B2 (en) * 2001-09-19 2005-01-04 Oklahoma Medical Research Foundation Treatment of sepsis with TAFI
EP1446138A4 (en) 2001-10-15 2007-03-14 Novartis Vaccines & Diagnostic TREATMENT OF AN INFECTIOUS DISEASE BY THE ADMINISTRATION OF A LOW DOSE OF A TISSUE THROMBOPLASTINE ACCESS PATHWAY INHIBITOR (TFPI)
US7345150B2 (en) * 2002-03-26 2008-03-18 Medical University Of Toledo Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
US7884068B2 (en) * 2002-03-26 2011-02-08 Assaly Ragheb A Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
EP1598074B1 (en) * 2003-02-28 2019-01-02 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
ES2522525T3 (es) * 2003-05-15 2014-11-14 Genentech, Inc. Métodos y composiciones para la prevención y el tratamiento de la sepsis
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
JP2007518062A (ja) * 2003-09-29 2007-07-05 バイオサイト インコーポレイテッド 敗血症を診断する方法および診断するための組成物
AU2005244249A1 (en) * 2004-03-17 2005-11-24 Novartis Vaccines And Diagnostics, Inc. Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (TFPI)
US20080305100A1 (en) * 2004-07-23 2008-12-11 Zlokovic Berislav V Activated Protein C Inhibits Undesirable Effects of Plasminogen Activator in the Brain
US20100284997A1 (en) * 2006-10-31 2010-11-11 Griffin John H Dosing regimen of activated protein c and variants having reduced anticoagulant activity
CA2681828A1 (en) 2007-03-28 2008-10-09 Universidad De Barcelona Cd6 products for the treatment of sepsis
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
WO2013151910A1 (en) * 2012-04-02 2013-10-10 Saint Louis University Methods and compositions for reducing the incidence of post-surgical adhesions
CA3044334A1 (en) 2016-11-18 2018-05-24 Institut D'investigacions Biomediques August Pi I Sunyer- Idibaps Combined cd6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
EP4201420A1 (en) * 2021-12-21 2023-06-28 Universität Regensburg Non-human bactericidal/permeability-increasing protein (bpi) for therapy of infections

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US5198541A (en) 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5308834A (en) 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5171739A (en) 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5627262A (en) 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
US5607916A (en) 1989-07-05 1997-03-04 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
AT402262B (de) 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
US5733872A (en) 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5643875A (en) 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
US5945399A (en) 1996-05-23 1999-08-31 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
AU1211700A (en) 2000-05-08
US20010006806A1 (en) 2001-07-05
BR9914735A (pt) 2001-07-03
EP1124573A1 (en) 2001-08-22
JP2002527490A (ja) 2002-08-27
CA2347250A1 (en) 2000-04-27
WO2000023101A1 (en) 2000-04-27
AU768075B2 (en) 2003-12-04
CN1324244A (zh) 2001-11-28
US6344197B2 (en) 2002-02-05
US20020044929A1 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
IL142248A0 (en) Methods for treating sepsis
GB0106312D0 (en) Process
GB9826874D0 (en) Process
GB9816385D0 (en) Process
GB2359314B (en) Technique for treating wells
EP1127060A4 (en) HYDROCARBON BORATE TREATMENT PROCESS
HK1039449A1 (zh) 治療多發性硬化的方法
GB9827884D0 (en) Process
HK1042847A1 (zh) 骨代謝異常症治療劑
GB9820195D0 (en) Process
GB9825424D0 (en) Process
GB9806527D0 (en) Process
GB9816564D0 (en) Process
EP1043994A4 (en) METHOD OF TREATING MULTIPLE SCLEROSIS
GB2335866B (en) Process
GB9828103D0 (en) Process
GB9820914D0 (en) Process
AU1167P (en) Treat xTriticosecale
GB9808948D0 (en) Improved dimerisation process
GB9813915D0 (en) Process
GB9809046D0 (en) Process
GB9813200D0 (en) Process
GB9813086D0 (en) Process
GB9814485D0 (en) Process
GB9813003D0 (en) Process